SCHEMBL2844045

SCHEMBL2844045

O=P(Cl)(N1CCOCC1)N1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.43
GAA P10253 2/20 0.42
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
ALPG P10696 1/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CA12 O43570 3/20 0.36
CA7 P43166 2/20 0.36
CA14 Q9ULX7 1/20 0.36
MGLL Q99685 1/20 0.33
ANPEP P15144 1/20 0.33
ALDH1A1 P00352 2/20 0.33
PKM P14618 1/20 0.33
CA1 P00915 2/20 0.32
CA9 Q16790 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409920 0.83 MAPT (0.43) MAPTGAAMMP1MMP3MMP8
SCHEMBL28287137 0.81 MAPT (0.42) MAPTGAAMMP1MMP3MMP8
SCHEMBL28237924 0.79 MAPT (0.41) MAPTGAAMMP1MMP3MMP8
SCHEMBL7455288 0.79 MMP1 (0.46) MAPTGAAMMP1MMP3MMP8
SCHEMBL9518240 0.79 GAA (0.41) MAPTGAAMMP1MMP3MMP8
SCHEMBL31220775 0.78
SCHEMBL1276983 0.77 MAPT (0.46) MAPTGAAMMP1MMP3MMP8
SCHEMBL11531391 0.74 MAPT (0.45) MAPTGAAMMP1MMP3MMP8
SCHEMBL29727668 0.74 MAPT (0.45) MAPTGAAMMP1MMP3MMP8
SCHEMBL273145 0.72 MAPT (0.43) MAPTGAAMMP1MMP3MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695257-A1 PROCESS FOR THE PREPARATION OF REMIMAZOLAM AND SALTS THEREOF Harman Finochem Limited (IN) 2026-02-18 EP claimed
WO-2024214109-A1 PROCESS FOR THE PREPARATION OF REMIMAZOLAM AND SALTS THEREOF HARMAN FINOCHEM LIMITED (IN) 2024-10-17 WO claimed
WO-2024137495-A9 FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF NAVINTA, LLC (US) 2024-07-25 WO claimed
WO-2024137495-A1 FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF NAVINTA, LLC (US) 2024-06-27 WO claimed
US-20240208980-A1 Fostemsavir Intermediates and Process for the Preparation Thereof NAVINTA, LLC 2024-06-27 US claimed
CN-117761193-A Analysis and detection method for rimazolam intermediate 上海药坦药物研究开发有限公司 2024-03-26 CN claimed
CN-117486930-A Phosphonamide flame-retardant nucleation difunctional additive for polyester and preparation method thereof 江苏康辉新材料科技有限公司 2024-02-02 CN claimed
CN-117229614-A Flame-retardant heat-resistant polylactic acid composition and preparation method thereof 江苏康辉新材料科技有限公司 2023-12-15 CN claimed
CN-112321594-B Preparation method of benzodiazepine medicine 扬子江药业集团有限公司 2022-05-20 CN claimed
US-11236064-B2 Method for preparing 3-[(3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-[1,4]-benzodiazepin-3-yl] propionic acid methyl ester, and compounds useful in that method MOEHS IBERICA S.L. (ES) 2022-02-01 US claimed
EP-3658545-B1 METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL]PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD MOEHS IBERICA SL (ES) 2021-08-11 EP claimed
US-20210139452-A1 METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD MOEHS IBERICA S.L. (ES) 2021-05-13 US claimed
CN-112321594-A Preparation method of benzodiazepine medicine 扬子江药业集团有限公司 2021-02-05 CN claimed
EP-3658545-A1 METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL]PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD Moehs Ibérica, S.L. (ES) 2020-06-03 EP claimed
WO-2019020790-A1 METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD MOEHS IBERICA S.L. (ES) 2019-01-31 WO claimed
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2026-05-21 US disclosed
EP-4711368-A1 AZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF CHENGDU MFS PHARMA. CO., LTD. (CN) 2026-03-18 EP disclosed
US-4307237-A ANTICONVULSANTS, SEDATIVES, MUSCLE RELAXANTS HOFFMANN-LA ROCHE INC. (US) 1981-12-22 US disclosed
US-4280957-A Imidazodiazepines and processes therefor HOFFMANN-LA ROCHE INC. (US) 1981-07-28 US disclosed
US-3974188-A PHOSPHATE THE LION DENTIFRICE CO., LTD. (JA) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139452-A1 METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD GABRA3, GRIK5, GABRA6 MAPT 2663/4885GAA 4104/4885MMP1 4780/4885
US-11236064-B2 Method for preparing 3-[(3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-[1,4]-benzodiazepin-3-yl] propionic acid methyl ester, and compounds useful in that method GABRA3, GRIK5, GABRA6 MAPT 2663/4885GAA 4104/4885MMP1 4780/4885
US-20240208980-A1 Fostemsavir Intermediates and Process for the Preparation Thereof FIP1L1, CYP3A4, FOS MAPT 1017/4885GAA 511/4885MMP1 4233/4885
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF STXBP1, HBB, UPF1 MAPT 3405/4885GAA 3170/4885MMP1 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.